Tag:
Questcor
Latest Headlines
Latest Headlines
Questcor stock reels as feds eye Acthar marketing
As if last week's reimbursement blow to Questcor Pharmaceuticals wasn't enough, the company today disclosed that the U.S. government is investigating its marketing practices. The stock dropped by 27%, on top of a 40% decline last week.
Aetna all but drops Questcor's Acthar drug; shares plummet
Easy come, easy go? Questcor Pharmaceuticals ($QCOR) got a big boost yesterday after an Oppenheimer analyst raised his price target on the stock, citing Medicaid rebate changes that could boost sales of its Acthar drug by almost $100 million next year. Today, Aetna all but dropped its coverage of Acthar--and the stock plummeted.
Questcor's looming Medicaid rebate liability
Later this year, Questcor will be hit by a wave of new Medicaid rebate claims on its pricey drug Acthar as managed-care plans take advantage of a rebate provision tucked into the federal healthcare
Four drugs look to pass FDA muster this month
Brian Orelli of The Motley Fool highlights four drugs--AstraZeneca's Brilinta, Questcor's Acthar Gel, Savient's Krystexxa and Novartis' Gilenia--that could gain FDA approval this month despite some
Stealth biotech picks up Questcor drug program
Xconomy has been digging into the regulatory paperwork to find out more about Evoke Pharma, a San Diego-based developer that's been operating in stealth mode. A quarterly report from Questcor shows
More meds doubling in price
Prices have ballooned by 100 percent or more for a growing number of drugs, according to a new study. In fact, the number of branded meds whose prices have grown that much could double this year from
Congress decries drug price-gouging
Congress raked some specialty pharma companies over the coals on Friday, accusing them of gouging patients with "staggeringly high prices." In a hearing, the Joint Economic Committee targeted
PBMs making big bucks off specialty drugs
Drugmakers aren't the only ones making money off the specialty drug trend . Specialty drugs, many of
